Medtronic and Schwarzer Cardiotek announce distribution agreement
Hemodynamic measurement stations update Munich Municipal Hospitals
evolution - hemodynamics 2018
Extended Medtronic EMEA co-marketing cooperation
Toshiba Medical Systems - European distribution agreement
Schwarzer Cardiotek introduces software version 2.2 for the electrophysiological measuring system EP-TRACER.
Schwarzer Cardiotek receives FDA 510(k) clearance for software version 2
EP-TRACER - The Film
New User Reports about EP-TRACER Portable
Schwarzer Cardiotek presents software version 2 of its electrophysiogical measuring system EP-TRACER
Schwarzer Cardiotek concludes filling of key management-level positions
Philips und Schwarzer Cardiotek conclude reseller agreement for the cardiology information system cardWorks
Schwarzer GmbH, Heilbronn Germany, And Cardiotek B.V., Maastricht, The Netherlands Announces That The Two Companies Will Merge Under The New Brand Of Schwarzer Cardiotek
Cardiotek Announces U.S. Commercialization of the EP-Tracer System Company to Showcase the System at 2014 HRS Meeting
SAN FRANCISCO, May 7, 2014 /PRNewswire/ -- Cardiotek B.V., a subsidiary of Schwarzer, a privately held medical device company focused on electrophysiologic (EP) and hemodynamic measurement systems, today announced it will commence commercialization of its EP-Tracer System following the 2014 Heart & Rhythm Society (HRS) Meeting in San Francisco, CA.
The EP-Tracer System is a recording device with a built-in dual-channel programmable stimulator that is currently used worldwide by key opinion leaders in the EP community. Targeted U.S. commercialization of the FDA approved EP-Tracer System will begin later this month as part of a comprehensive U.S. go-to-market strategy.
The EP-Tracer System provides excellent signal quality controlled by a compact, single-user unit. The easy-to-use integrated programmable stimulator, which allows stimulation on all intracardiac inputs, has three model options and offers up to 102 intracardiac channels. System customization allows for portable, mobile, and stationary configurations to optimally suit the customer needs and improve system utilization across EP labs.
"Throughout the majority of my career and for thousands of ablations, I have used the EP-Tracer System as my primary EP recording system. The system offers superior signal quality in a compact, single-user system," commented Dr. Josep Brugada M.D. Ph.D., Electrophysiologist and Medical Director at the University of Hospital Clinic Barcelona in Spain. "The EP-Tracer System provides a simplified approach to therapeutic procedures."
EP studies are used to diagnose and treat a variety of conditions in which the heart beats abnormally, including atrial fibrillation (AF). During EP testing, the recording system acquires, measures and records intracardiac signals as well as stimulates the heart to assist the physician in the diagnosis and treatment. Electrophysiology is a $2.5 billion global market that is growing at nearly 10% annually.
"The EP-Tracer System is one of the preferred recording devices in Europe with an installed base of approximately 1,000 systems," commented Frank-P. Klein, President and Chief Commercial Officer of Schwarzer. "We are excited to bring the EP-Tracer System to the U.S. and believe it will transform the market by offering physicians a higher quality and more portable system for EP procedures."
The EP-Tracer System received FDA 510(k) clearance in March 2014 and will be on display at booth #711 at the HRS meeting, May 7th-10th.